Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
This study has been completed.
Sponsor:
Alcon Research
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00069719
First received: September 30, 2003
Last updated: August 4, 2008
Last verified: August 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine the safety and IOP-lowering ability of a test compound in patients with open-angle glaucoma or ocular hypertension.
| Condition | Intervention | Phase |
|---|---|---|
|
Open-Angle Glaucoma Ocular Hypertension |
Drug: Glaucoma therapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients |
Resource links provided by NLM:
Further study details as provided by Alcon Research:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension;
- logMAR visual acuity not worse than 0.6.
Exclusion Criteria:
- Clinically relevant ophthalmic or systemic conditions may be excluded.
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00069719 History of Changes |
| Other Study ID Numbers: | C-02-33, C-02-33 |
| Study First Received: | September 30, 2003 |
| Last Updated: | August 4, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Alcon Research:
|
open-angle glaucoma ocular hypertension POAG |
Additional relevant MeSH terms:
|
Glaucoma Glaucoma, Open-Angle Hypertension Ocular Hypertension |
Eye Diseases Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 19, 2013